|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010927,
umls-concept:C0011306,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0042196,
umls-concept:C0278883,
umls-concept:C0282461,
umls-concept:C0439859,
umls-concept:C1257890,
umls-concept:C1708063,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-3-24
|
|
pubmed:abstractText |
This randomized phase III trial was designed to demonstrate the superiority of autologous peptide-loaded dendritic cell (DC) vaccination over standard dacarbazine (DTIC) chemotherapy in stage IV melanoma patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AVISK EKE,
pubmed-author:BeckerJ CJC,
pubmed-author:BergerTT,
pubmed-author:BröckerE-BEB,
pubmed-author:DC study group of the DeCOG,
pubmed-author:EdlerLL,
pubmed-author:GrabbeSS,
pubmed-author:JonuleitHH,
pubmed-author:KämpgenEE,
pubmed-author:KamarashevJJ,
pubmed-author:KeikavoussiPP,
pubmed-author:LIJ TJT,
pubmed-author:NestleF OFO,
pubmed-author:RittgenWW,
pubmed-author:SchadendorfDD,
pubmed-author:Schuler-ThurnerBB,
pubmed-author:SchulerGG,
pubmed-author:SuckerAA,
pubmed-author:TüttenbergAA,
pubmed-author:UgurelSS,
pubmed-author:Zimpfer-RechnerCC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
563-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
|
|
pubmed:affiliation |
Skin Cancer Unit, German Cancer Research Center & University Hospital Mannheim, Mannheim. d.schadendorf@dkfz.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
